 CAMBRIDGE, Mass., Sept. 20, 2021 GLOBE NEWSWIRE -- Annexon, Inc. Annexon Nasdaq: ANNX, a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye, today announced that the company will host its second virtual C1q Series event on Monday, September 27, 2021, at 10:00 a.m. ET, to discuss its neurodegeneration franchise. Annexons RD event will include presentations from the executive team as well as prominent key opinion leaders. 